drug_type
RELEVANT_DRUG
intervention_type
biologic (monoclonal antibody)
drug_description
Anti-CD2 monoclonal antibody biologic that binds CD2 on T cells and NK cells, blocks CD2–CD58 costimulatory signaling, and preferentially depletes/modulates memory T cells to reduce alloimmune and autoimmune activity after liver transplant.
nci_thesaurus_concept_id
C38685
nci_thesaurus_definition
A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.
drug_mesh_term
siplizumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody against CD2 that binds T and NK cells, blocks CD2–CD58 costimulatory signaling, and depletes/modulates CD2+ (especially memory) T cells via immune effector mechanisms (e.g., ADCC/CDC), suppressing alloimmune and autoimmune activity.
drug_name
Siplizumab
nct_id_drug_ref
NCT06455280